Sorry, but the browser version you are currently using is not supported by this website. We recommend that you update or download a more recent version.

We innovate


by embedding connectivity in therapeutics
and medical intelligence in software

With excellence and innovation at heart,

Voluntis designs
state-of-the-art solutions

for chronic and rare diseases to empower patients by embedding intelligence in mobile phones and to simplify care provision by powering health data management.

We innovate

healthcare solutions

by embedding connectivity in therapeutics
and medical intelligence in software

With excellence and innovation at heart,

Voluntis designs
state-of-the-art solutions

for chronic and rare diseases to empower patients by embedding intelligence in mobile phones and to simplify care provision by powering health data management.

Voluntis ensures
continuity during
COVID-19 crisis

Our teams are working from home and remain 100% committed to maintaining excellent quality of service as we continue to create and operate innovative digital therapeutics and telemonitoring solutions.



Voluntis was founded in 2001 by three entrepreneurs who believed that innovative medical solutions built with advanced information technologies would improve medical real-life outcomes and thus increase healthcare system efficiency. This would transform patient lives, enhance medical practices and quality of care.

Every day, Voluntis teams seek to invent secure, collaborative and patient-centric digital health solutions with a unique combination of web and mobile development excellence, medical and regulatory expertise and certified quality-oriented processes. With more than 600,000 patients managed and more than 50 programs deployed, our track record speaks for itself.

  • 600,000
    patients managed
  • 50
    programs deployed

At Voluntis, we are all guided by clear and simple values:

  • Patient focus: we are committed to changing the daily lives of patients by addressing their unmet needs and by empowering them to manage their chronic conditions.
  • Passion for innovation: we design next-generation solutions that combine digital and medical expertise to solve the daily problems of patients and caregivers.
  • Respect and integrity: everyday, we take care of the people we touch, our patients, customers, partners and employees.
  • Drive for excellence: in everything we do, we behave ethically and we strive to attain the highest level of quality. Always working to enhance our processes, we are certified MDSAP USA & Canada and ISO 13485 (regarding quality management systems). We are also compliant with ISO 14971 standards (risk management). Our design methodologies embed the harmonized IEC 62304 and IEC 62366 standards (for medical device software).


Chief Executive Officer and Founder

Pierre has more than 15 years of international experience in software medical devices, disease management and telemedicine solutions in Europe and the United States. Before founding Voluntis in 2001, Pierre worked with General Electric Medical Systems and with HealthCenter Internet Services, an online cardiology EMR solution vendor in San Francisco. In addition, Pierre is the Director of Syntec Numérique, where he leads the telemedicine workgroup, co-leader of CSIS-CSF’s e-health workgroup and e-health advisor within Nouvelle France Industrielle’s health steering committee. Pierre is a graduate of the Ecole Centrale Paris engineering school.



Chief Business Officer and Founder

Romain is Chief Business Officer of Voluntis. He heads the Business unit from Cambridge, MA. He has more than 15 years of experience in digital health and software medical devices. He holds an MSc from École Centrale Paris in applied mathematics.

Matthieu Plessis

Matthieu PLESSIS

Chief Financial Officer

Matthieu has 25 years of experience in various finance positions in the pharmaceutical, telecom and IT industries. Prior to joining Voluntis, he was CFO of eFront, a global financial software vendor. In this position, he successfully supported the group’s rapid growth as well as it’s finance and M&A operations. Previously, he worked for Glaxo and SFR-Cegetel. He is a graduate of ESSCA management school.

Dr Geneviève D'ORSAY

Geneviève D'ORSAY

Chief Medical Officer

Geneviève has more than 20 years of experience in the life sciences industry. Before joining Voluntis, she was Medical Affairs Director for Johnson & Johnson Medical Devices & Diagnostics for France & BeNeLux. Prior to this position, she worked for Altana Pharma, Chiesi and Bioprojet. She holds a doctorate in medicine and a degree in pharmacology and clinical research from University of Paris VI as well as a degree in pharmacovigilance from University Descartes, Paris.

Guillaume Floch


Chief Financial Officer

Guillaume has more than 20 years of professional experience in finance, first in an audit firm, then in the biopharmaceutical sector in financial control and then in financial management. He held the position of Chief Financial Officer of Hybrigenics (biotechnology) for more than 10 years, after having been Administrative and Financial Manager at Zeneus Pharma (acquired by Cephalon). Guillaume holds a DESCF and a MSTCF from the University of Paris V.

Matthieu Plessis

Matthieu PLESSIS

Chief Financial Officer

Matthieu has 25 years of experience in various finance positions in the pharmaceutical, telecom and IT industries. Prior to joining Voluntis, he was CFO of eFront, a global financial software vendor. In this position he successfully conducted an IPO in Europe, as well as the trade public to private sale of the company. Previously, he worked for Glaxo, SFR-Cegetel and Cegetel Enterprises. He is a graduate of ESSCA management school.

Etienne VIAL

Etienne VIAL

Chief Technology Officer and Founder

Etienne manages the innovation activities at Voluntis. Etienne has more than 12 years of experience in building frameworks, deploying m-health solutions and developing algorithms, analytic suites and interoperable software. He is a graduate of the École Centrale Paris engineering school.



Senior Vice-President Global Quality & Regulatory Affairs

Raffi has 15+ years of experience in the medical device industry. Prior to joining Voluntis, Raffi was Manager at Hutchinson Santé, healthcare subsidiary of Hutchinson Group, where he headed R&D, manufacturing and regulatory affairs in an international environment. Raffi is a graduate of the Ecole Nationale Superieure de Chimie de Mulhouse and holds a PhD in polymer science. He also holds an MBA from ESCP Europe business school.



Senior Vice-President Global Strategic Alliances

Damien is charged of Voluntis' pharmaceutical alliances and real-world evidence capabilities, notably in the fields of outcomes measurement and data valuation. He trained in the UK as a pharmacist and computer scientist. He has over 15 years of experience in the pharmaceutical industry and in frontline clinical healthcare (at Portsmouth Hospitals NHS Trust and multiple pharmacies). He notably worked at AXA, where he helped build an operational framework to handle outsourced medical information services for pharmaceutical partners. In 2005 he led the preparation for the first ever UK Medicines and Healthcare Products Regulatory Agency inspection of this type of provider. He joined Voluntis in Paris in 2008 to take the helm of its quality division, obtaining QMS certification for ISO:13485 in 2010 and VITM/Diabeo’s CE Mark in 2013.

Eric Bavière


Senior Vice-President Solution Design & Delivery

Eric is responsible of the Design and Delivery department, including project activities, functional design, Human Factors, UX Design and labelling. With more than 17 years of experience in medical software devices, Eric has held positions in strategy, marketing and management. He has also worked on the design and deployment of numerous projects in different therapeutic areas, both in Europe and North America. He holds a degree in Computer and Network Engineering.

Guillaume Moucheroud


Vice-President Performance, Safety & Architecture

Guillaume is responsible for the architecture and performance of our solutions, algorithms, risk analysis and cybersecurity. He has 20 years of experience as a system engineer and manager. After having worked for major groups (IBM, Renault, PSA) on embedded software safety, he has dedicated most of his career to the innovative medical device industry (Diagnostica Stago, Carmat SA, Voluntis), combining his technical, regulatory and managerial expertise. Guillaume is a graduate of the Ecole Supérieure d'Electricité (Supélec) and Sciences-Po Paris.

Adeline Jospe

Adeline JOSPE

Vice-President Human Resources

Vice-President of Human Resources, Adeline joined Voluntis in 2017. Graduated with a Master's degree in Labor Law, a DEA in Labor and Trade Union Law and a Master's degree in Human Resources Management, Adeline has more than 15 years of experience as a Lawyer and Human Resources Manager. Before joining Voluntis, Adeline worked for nearly 10 years for the digital services company Alten.

Aurore Beaume


Vice-President of Global Business Development

Aurore has over 10 years of experience in innovation and healthcare, in particular in developing strategy, business models and partnerships. Before joining Voluntis, she managed the innovation consulting practices for several firms such as Altran (Arendi Consulting), Erdyn and Sogeti High Tech. She specialized in life sciences, biotechnology, healthcare and digital. She created innovation strategies and business models for start-ups as well as large groups such as Phillips, bioMérieux and Pierre Fabre. She graduated from Ecole Polytechnique and Chimie ParisTech (National Chemical Engineering Institute in Paris) and also holds a PhD in pharmaceutical organic chemistry from UPMC (formerly Pierre and Marie Curie University, part of the Sorbonne University).

  • Pierre LEURENT

    Chief Executive Officer and Founder


  • Romain MARMOT

    Chief Business Officer and Founder


  • Etienne VIAL

    Chief Technology Officer and Founder


  • Dr Geneviève D'ORSAY

    Chief Medical Officer


  • Guillaume Floch

    Chief Financial Officer


  • Aurore Beaume

    Vice-President of Global Business Development


  • Damien MCKEON

    Senior Vice-President Global Strategic Alliances


  • Eric Bavière

    Senior Vice-President
    Design & Delivery


  • Guillaume Moucheroud

    Vice-President Performance,
    Safety & Architecture



    Senior Vice-President Global Quality & Regulatory Affairs


  • Adeline Jospe

    Vice-President Human Resources

    Adeline JOSPE

Eric Elliott

Chairman of the Board of Directors

In his most recent role as Prime Therapeutics' President and Chief Executive Officer, Eric Elliott was responsible for all operating and strategic aspects of the full service pharmacy benefit management company. With approximately $17 billion in annualized drug spend under management, Prime Therapeutics is the fourth largest pharmacy benefit manager in the United States, servicing 23 health plans, other smaller pharmacy benefit managers (PBMs), and employer direct customers. Critical to the success of Prime Therapeutics, Eric led the partnership with Blue Cross and Blue Shield Plans to ensure members receive the highest quality of care while managing appropriate pharmaceutical costs and trends. Under Elliott's leadership, Prime was recognized locally and nationally by prominent publications and organizations for its employee engagement, healthy workplace, highest quality and care of service for members, and business growth. With experience running three integrated PBMs, Eric is skilled in leading and growing businesses to include line and segment expansions. He previously served as president of Cigna's Pharmacy Management and Voluntary businesses and has held senior executive level positions at Aetna, PCS HealthSystems and Rite Aid Corporation. Elliott received his bachelor's degree in management and finance, and a Master of Business Administration from Temple University in Philadelphia. He has served for many years on the board of directors at Prime, The Main Street America Group, the Pharmaceutical Care Management Association and the Twin Cities American Heart Association. Elliott also serves on The Wall Street Journal CEO Council.


Director and Chief Executive Officer

Pierre has more than 15 years of international experience in software medical devices, disease management and telemedicine solutions in Europe and the United States. Before founding Voluntis in 2001, Pierre worked with General Electric Medical Systems and with HealthCenter Internet Services, an online cardiology EMR solution vendor in San Francisco. In addition, Pierre is the Director of Syntec Numérique, where he leads the telemedicine workgroup, co-leader of CSIS-CSF’s e-health workgroup and e-health advisor within Nouvelle France Industrielle’s health steering committee. Pierre is a graduate of the Ecole Centrale Paris engineering school.

Jan Berger


Dr. Berger is a tri-sector healthcare executive with proven results in private, public and government services over the last 30 years. In 2009, Dr. Berger founded Health Intelligence Partners as a health care consultancy where she has advised in 14 countries with both health organizations and national ministries of health. Prior to that, she served as Senior Vice President, Chief Clinical Officer and Innovation Officer for CVS Health/Caremark. She currently sits on the boards of Cambia Health Solutions, a multi-state Blue Cross Blue Shield plan; GNS Healthcare, a healthcare data analytics company; Tabula Rasa, a medication safety and management company; and Accent Care, a home health and palliative care organization. Dr. Berger is an assistant professor at Northwestern University School of Medicine and School of Communication in Chicago, Illinois. She is a renowned expert in consumer engagement and medication adherence and has authored four books and numerous publications on these topics. She holds both a Doctor of Medicine degree and a Master’s in Jurisprudence from Loyola University (Chicago, Illinois).

Laurent Higueret


Laurent is an investment director in the Large Venture Fund at Bpifrance, the French Sovereign Wealth Fund, specializing in healthcare and life sciences investments. He currently serves as board director at Voluntis (digital therapeutics) and formerly at Biom’Up (biosurgery) and Poxel (type 2 diabetes). Laurent is also a board observer at Enyo Pharma (HBV, NASH) and GenSight Biologics (gene therapy); and follows Bpifrance’s investments in DBV Technologies (food allergies) and MedDay Pharmaceuticals (neurodegenerative diseases).
Before joining Bpifrance in 2014, he spent six years as an investment banker with BNP Paribas’ Healthcare M&A Group.
Laurent qualified as a Doctor of Pharmacy at the University of Bordeaux and holds a Master Degree in Financial Engineering from the EM Lyon Business School.

Viviane Monges


Viviane Monges has 30 years of experience as a Senior Executive in the finance function. She has had a successful career in international companies, holding positions in Europe, Asia and the United States, mostly in the healthcare sector. After five years at Agence France Presse in Paris and then Hong Kong, she joined the pharmaceutical industry with Wyeth, first in the French subsidiary as director of management control, then at the group's head office in Philadelphia, as Chief Financial Officer of the Europe Region, then of the Pharma Business Unit (USD 6 billion). She took an active role in many projects to transform the company, organisationally, strategically and in mergers & acquisitions and to establish the Sarbanes-Oxley rules on internal control. In 2006, Viviane joined the OTC Division at Novartis as Chief Financial Officer, Europe. She took part in many key projects, including a reorganisation of the Europe Region as well as the establishment of shared service centres. Next, she served as Global CFO of the OTC Division based in the United States (USD 3.5 billion) during the Prevacid launch. In 2010, Viviane was appointed CFO of Galderma, a Swiss pharmaceutical group specialised in dermatology (USD 2.5 billion). This group, a joint venture of Nestlé and L'Oréal, is an industry leader in Rx, OTC, and Aesthetics. In 2014, following Nestlé's acquisition of all of Galderama's shares, the latter became Nestlé Skin Health. In 2015, Viviane joined Nestlé as CFO of the Business Excellence Department, which groups together the worldwide support functions (finance, HR, IT, procurement, digital and property). For three years, Viviane has been responsible for a major programme to transform the group. In 2018, Viviane decided to focus on directorship. She is a member of the board of directors of UCB and Novo Holdings. Viviane is a graduate of ESCP, a French national, and a resident of Lausanne.

Franck Noiret


Franck Noiret is Managing Director of Innovation Capital at LBO France, a leading private equity firm with over 3 billion euros under management. He joined Innovation Capital in 2005 as General Partner, and LBO France in 2016 when the firms joined forces. He is currently investing in Digital Health companies in Europe through the Services Innovants Santé et Autonomie (SISA) fund. With over 20 years of investment experience in Technology and Healthcare, Franck Noiret is currently board member of Voluntis, Entrepreneurs & Investisseurs Technologies, Kayentis, Omni Orthopaedics (US), Zesty (UK) and observer of Ekinops (EKI / Euronext). Prior to joining Innovation Capital, Franck Noiret was Director at Apax Partners in Paris where he was responsible for investments in Technology and Telecoms ranging from venture capital to growth LBO. From 1995 to 2000, Franck Noiret was Principal Banker at the European Bank for Reconstruction and Development (EBRD) where he was responsible for private and public sector investment projects in Central and Eastern Europe. De 1989 à 1993, Franck Noiret was a banker in the City of London for Société Générale after starting his career as an auditor at Arthur Andersen in Paris. Franck Noiret has a MBA from the Wharton School (US) and a Master in Corporate Finance from Paris-Dauphine University. He graduated with the highest distinction from Sciences Po Paris.


We firmly believe that the unprecedented advancement of information
technologies will contribute to solving certain healthcare system issues,
notably related to chronic disease expansion.

At Voluntis, we believe these remarkable changes are the pivotal factors that are already transforming healthcare systems. We are poised and ready to catapult the best from advanced technologies to improving healthcare.

Committed to this vision, Voluntis designs digital therapeutics that transform healthcare by:

  • designing integrated care services
  • aligning the interests of patients, providers and payers
  • driving costs down while improving quality
  • establishing a collaborative relationship between patients and their doctors



At Voluntis, we develop state-of-the-art digital therapeutics to accompany
and enhance a specific medication or medical device.

We design our digital therapeutics in a user-friendly manner
to augment the real-life value of therapeutics by:

For example, we design clinical algorithms that support decision-making, such as medication dosage.

For example, we securely connect patients with caregivers to activate remote operations, such as monitoring, treatment adjustment or coaching.

For example, we promote data sharing between doctors and patients to foster engagement and enable effective task delegation among healthcare professionals so as to optimize time.

As an accompaniment to existing medication or medical devices, digital therapeutic apps aim to monitor side effects, guide symptom management, promote protocol adherence, recommend dosage or connect patients with their healthcare teams.

According to prevailing regulations, our digital therapeutics could be classified as a software medical device. To strictly comply with regulations, Voluntis has developed extensive regulatory expertise and implemented high quality standards.

As such, digital therapeutics have the potential to empower patients, prevent complications and, ultimately, augment the real-life value of a medication.

We conduct clinical studies to demonstrate the value and medical benefits of our digital therapeutics. In the diabetes m-health field, our digital therapeutic solution is the most extensively studied on the market.

Voluntis develops proprietary digital therapeutics but also provides partners with development and regulatory capabilities to elaborate their own.


Theraxium is a comprehensive and highly flexible platform that transforms health data into medical intelligence for better care.

Voluntis develops proprietary digital therapeutics but also provides partners with development and regulatory capabilities to elaborate their own digital solution based upon its Theraxium core system architecture.

Operated on the Cloud, Theraxium is a modular
web-based and mobile platform that can:

Management of device interoperability and seamless integration.

Security management and compliance with privacy rules.

Through configurable roles and workflows to coordinate the activities of care providers.

Analysis and retrieval of relevant information, using an analytics suite that incorporates clinical algorithms, automated notification or dashboards to support medical decisions.

Automated effective recall of software medical devices.

The cornerstone

A modular platform, Theraxium enables healthcare organizations to monitor patients remotely, support patient assistance programs (therapeutic education for instance), track adverse events and prompt compliance.

Theraxium is also the cornerstone of our digital therapeutics. Tailored to design mobile applications, Theraxium is the underlying platform of our solutions dedicated to diabetes, respiratory diseases, cancer, hemophilia and anticoagulation.

Proven reliability

A highly flexible framework, Theraxium has proven its reliability through its implementation in 50+ programs covering more than 20 therapeutic fields. Six top 10 pharmaceutical leaders have deployed Theraxium to support patient-centric initiatives. It has provided support and monitoring to over 610,000 patients in 12 countries.

With over 50 e-health and m-health projects deployed, the Voluntis team has developed a unique expertise in developing software medical devices.

We combine flexibility with regulatory compliance; our quality certified project methodology aims to deliver state-of-the-art products and solutions by following the Agile Manifesto, relying on an interactive approach that encourages:

  • interaction
  • task parallelization
  • responsiveness
  • and customer collaboration

Beyond being your single point of contact, your Voluntis project manager ensures that your project fully meets your expectations, timeline and budget throughout design, development, validation and delivery phases.

In addition to traditional software management, your Voluntis project manager addresses all topics specific to medical device manufacturing (such as human factors, product/patient risk management and clinical evaluations) with our experts.

Focused on patient safety and driven by excellence,
Voluntis’ teams put quality at the heart of what they do.

Since 2008, our Quality Assurance department has ensured compliance with regulations and standards, trained employees in our quality processes and managed our product regulatory clearance and registration.


Our diabetes solutions are designed to support type 1 and type 2 diabetes patients throughout the insulin therapy pathway. Our digital therapeutics in diabetes are prescription medical devices.


Insulia® provides automated basal insulin dose recommendations and coaching messages for people with type 2 diabetes while enabling the health care team to remotely monitor progress. A healthcare practitioner prescribes Insulia using their dedicated web portal and sets up the treatment plan rules that will adjust basal insulin dosing based on the person’s specific needs. The user then receives an activation code to get started with their personalized app. Once downloaded, the app uses blood glucose readings and any hypo symptoms to recommend doses in real-time. These are constantly updated using clinical algorithms built into the application. Data is automatically shared with the health care team, who can remotely monitor the patient’s progress toward their goal thanks to tailored notifications. This enables providers to deliver tailored telemedicine services, a practice increasingly supported by payers worldwide.

To learn more, visit insulia.com


Diabeo® is a digital solution for type 1 and type 2 patients treated on a basal-bolus insulin regimen. It provides therapeutic and decision-making support for effective diabetes management to help adult patients dose their basal and bolus insulin, facilitate interactions between patients and their healthcare professionals, support remote management and the implementation of telemedicine services. Diabeo® suggests insulin dosage, through algorithmic calculations that are specific to the patient and based on their particular doses. Diabeo® was conceived as part of an extensive clinical program including 3 clinical studies conducted in partnership with Sanofi and the CERITD over the past 10 years.

Diabeo® is a regulated healthcare product that was granted a CE Mark in 2013. Diabeo® is not approved for use in the United States.

Diabeo® is a registered trademark of Sanofi.
Insulia® is a registered trademark of Voluntis.


First FDA Class II Software-as-a-Medical Device to be Marketed for Use Across All Cancer Indications.
Based on a mobile app for patients and a web portal for HCPs, Oleena® enables self-management of symptoms and remote monitoring by care teams. Oleena® provides patients with personalized insights to self-manage the symptoms they experience over the course of their disease. Once Oleena® has been prescribed by a care team, patients are guided with real-time and personalized recommendations on what to know and what to do. These recommendations include personalized coaching for symptom management as well as on-demand directions for initiation and dosage of supportive therapies based on the patient’s individual care plan. Healthcare teams get access to automated and adaptative insights on patient’s symptoms in order to support patients wherever they are, whenever they need it.
Oleena® supports the self-management of common side effects experienced by cancer patients such as diarrhea, pain, nausea and vomiting. Powered by a comprehensive set of proprietary algorithms, Oleena® is able to support patients across a wide range of cancer types and anticancer treatments (including chemotherapy, immuno-oncology drugs and targeted therapies, such as PARP, PI3K, CDK4/6 inhibitors).
Discover Oleena®

Ovarian cancer

eCO (e-Cediranib Olaparib) application was designed for patient self-reporting and management of hypertension and diarrhea using remote monitoring.
In 2016, in collaboration with AstraZeneca and the US National Cancer Institute (NCI), eCO was assessed as a digital therapeutic for women undergoing treatment for recurrent platinum-sensitive high-grade ovarian cancer in clinical trial of cediranib in combination with olaparib.
In 2018, the results were published in JCO Clinical Cancer informatics. The authors (J.Liu et al), highlighted feasibility, usability and perceived satisfaction with the use of the digital therapeutic and related healthcare team webportal.
Patients provided positive responses on the use of the eCO app. They indicated feeling more involved in their care and better connected with their healthcare team. Hypertension and diarrhea events reported via the eCO app allowed rapid response and positive overall patient experience.

Theraxium Oncology

Theraxium Oncology is the cornerstone software platform for all digital therapeutics developed by Voluntis in the field of cancer treatment. Its technology embeds specific modules to design and simulate algorithms: medical rules are coded in domain specific language with a high level of granularity to reflect temporality and contextualization according to an expert methodology. Voluntis has leveraged these modules to design an off-the-shelf library of clinical algorithms, which can be furthered customized.
The platform leverages digital therapeutics to empower patients so they can self-manage their symptoms, experienced when receiving cancer treatments, in coordination with care teams. 
Theraxium Oncology was born after 4 years of research and development in partnership with patients, life science partners and cancer institutes. Theraxium Oncology also integrates modules with predefined UX templates and configurable workflows.
The platform offers a scalable architecture to develop a full suite of solution. It enables elaborate data analytics and remote maintenance of digital therapeutics.
Oleena®, the first digital therapeutic obtaining market authorization in oncology is powered by Theraxium Oncology.
Discover Theraxium Oncology


In anticoagulation treatments, compliance is crucial: the INR (International Normalized Ratio) must be regularly measured to ensure the appropriate dosage of the vitamin K antagonist treatment.

In collaboration with Roche Diagnostics, Voluntis has developed a digital therapeutic to enhance the CoaguChek INR self-testing device.

This solution, named CoaguChek Link, centralizes the INR data measured by patients, connects patients with the independent diagnostic testing facility and enables effective telemonitoring by healthcare professionals.

Thus, CoaguChek Link simplifies care delivery, ensures compliance and enables doctors and patients to stay connected and work together on managing the anticoagulant treatment.


In hemophilia, we work to help patients manage their condition. Our innovative solution aims to simplify the remote monitoring of bleeding events as well as inventory medication management.